Latigo Biotherapeutics (LTGO) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines targeting Nav1.8 ion channels.

• Lead candidates LTG-001 (acute pain) and LTG-321 (chronic musculoskeletal pain) are oral Nav1.8 inhibitors; additional pipeline includes LTG-418 and other ion channel modulators.

• Strategy includes both oral and IV formulations, with plans to expand into multi-modal pain management and alternative delivery methods.

• Initial focus is on musculoskeletal pain, with future potential in neuropathic pain.

Financial performance and metrics

• Net losses of $61.2 million in 2024 and $109.2 million in 2025; accumulated deficit of $266.1 million as of March 31, 2026.

• Cash and cash equivalents of $42.2 million as of March 31, 2026.

• Operating expenses driven primarily by R&D, with $99.5 million spent in 2025.

• Substantial additional capital will be required to fund ongoing operations and clinical development.

Use of proceeds and capital allocation

• Net proceeds from the IPO, together with existing cash, will be used to advance LTG-001 through Phase 3 trials and NDA submission, LTG-321 through Phase 2 and into Phase 3, and for further R&D including LTG-418.

• Additional funds allocated for working capital, general corporate purposes, and potential strategic investments.